Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Summit Therapeutics (NASDAQ: SMMT) recently reported Ivonescimab’s Phase 3 results from study conducted in China that showed ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

A letter from the FDA rejecting Merck Sharpe & Dohme Corp.'s proposed label warning that its osteoporosis drug Fosamax could cause stress fractures doesn’t preempt state law claims alleging the ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

The pharmaceutical solvents market size is securing a valuation of USD 3.9 Billion in 2023 and is projected to reach USD 6.1 ...

Oral Solid Dosage Pharmaceutical Formulation Market is projected to achieve US$ 8,95,636.0 million by 2034 at a CAGR of 3.7%.

It was one of those conversations you never forget. We were discussing – of all things – the Covid injections, and I was questioning the early ‘safe and effective’ claims put forward by the pharmaceut ...

Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.